Format
Sort by

Send to

Choose Destination

Links from Books

Items: 1 to 20 of 21

1.

Metastatic non-small cell lung cancer management: novel targets and recent clinical advances.

Riess JW, Wakelee HA.

Clin Adv Hematol Oncol. 2012 Apr;10(4):226-34.

PMID:
22706483
2.

Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease.

National Research Council (US) Committee on A Framework for Developing a New Taxonomy of Disease.

Washington (DC): National Academies Press (US); 2011.

3.

Diagnosing the decline in pharmaceutical R&D efficiency.

Scannell JW, Blanckley A, Boldon H, Warrington B.

Nat Rev Drug Discov. 2012 Mar 1;11(3):191-200. doi: 10.1038/nrd3681. Review.

PMID:
22378269
4.

The innovative medicines initiative: a European response to the innovation challenge.

Goldman M.

Clin Pharmacol Ther. 2012 Mar;91(3):418-25. doi: 10.1038/clpt.2011.321. Epub 2012 Feb 8. Review.

PMID:
22318619
5.

2011 FDA drug approvals.

Mullard A.

Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4. doi: 10.1038/nrd3657. No abstract available.

PMID:
22293555
6.

A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.

Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Dřevínek P, Griese M, McKone EF, Wainwright CE, Konstan MW, Moss R, Ratjen F, Sermet-Gaudelus I, Rowe SM, Dong Q, Rodriguez S, Yen K, Ordoñez C, Elborn JS; VX08-770-102 Study Group.

N Engl J Med. 2011 Nov 3;365(18):1663-72. doi: 10.1056/NEJMoa1105185.

7.

Quantifying factors for the success of stratified medicine.

Trusheim MR, Burgess B, Hu SX, Long T, Averbuch SD, Flynn AA, Lieftucht A, Mazumder A, Milloy J, Shaw PM, Swank D, Wang J, Berndt ER, Goodsaid F, Palmer MC.

Nat Rev Drug Discov. 2011 Oct 31;10(11):817-33. doi: 10.1038/nrd3557. Review.

PMID:
22037040
8.

Discovery and preclinical validation of drug indications using compendia of public gene expression data.

Sirota M, Dudley JT, Kim J, Chiang AP, Morgan AA, Sweet-Cordero A, Sage J, Butte AJ.

Sci Transl Med. 2011 Aug 17;3(96):96ra77. doi: 10.1126/scitranslmed.3001318. Erratum in: Sci Transl Med. 2011 Sep 28;3(102):102er7.

9.

Reengineering translational science: the time is right.

Collins FS.

Sci Transl Med. 2011 Jul 6;3(90):90cm17. doi: 10.1126/scitranslmed.3002747.

PMID:
21734173
10.

The n-of-1 clinical trial: the ultimate strategy for individualizing medicine?

Lillie EO, Patay B, Diamant J, Issell B, Topol EJ, Schork NJ.

Per Med. 2011 Mar;8(2):161-173.

11.

Establishing Precompetitive Collaborations to Stimulate Genomics-Driven Product Development: Workshop Summary.

Institute of Medicine (US) Roundtable on Translating Genomic-Based Research for Health.

Washington (DC): National Academies Press (US); 2011.

12.

The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics.

Huang R, Southall N, Wang Y, Yasgar A, Shinn P, Jadhav A, Nguyen DT, Austin CP.

Sci Transl Med. 2011 Apr 27;3(80):80ps16. doi: 10.1126/scitranslmed.3001862.

13.

Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers.

Eichler HG, Bloechl-Daum B, Abadie E, Barnett D, König F, Pearson S.

Nat Rev Drug Discov. 2010 Apr;9(4):277-91. doi: 10.1038/nrd3079. Epub 2010 Feb 26. Review.

PMID:
20186141
14.

How to improve R&D productivity: the pharmaceutical industry's grand challenge.

Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, Schacht AL.

Nat Rev Drug Discov. 2010 Mar;9(3):203-14. doi: 10.1038/nrd3078. Epub 2010 Feb 19.

PMID:
20168317
15.

Lessons from 60 years of pharmaceutical innovation.

Munos B.

Nat Rev Drug Discov. 2009 Dec;8(12):959-68. doi: 10.1038/nrd2961.

PMID:
19949401
16.

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.

Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, Nardone J, Lee K, Reeves C, Li Y, Hu Y, Tan Z, Stokes M, Sullivan L, Mitchell J, Wetzel R, Macneill J, Ren JM, Yuan J, Bakalarski CE, Villen J, Kornhauser JM, Smith B, Li D, Zhou X, Gygi SP, Gu TL, Polakiewicz RD, Rush J, Comb MJ.

Cell. 2007 Dec 14;131(6):1190-203.

17.

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial.

Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, Avedisova AS, Bardenstein LM, Gurovich IY, Morozova MA, Mosolov SN, Neznanov NG, Reznik AM, Smulevich AB, Tochilov VA, Johnson BG, Monn JA, Schoepp DD.

Nat Med. 2007 Sep;13(9):1102-7. Epub 2007 Sep 2. Erratum in: Nat Med. 2007 Oct;13(10):1264.

PMID:
17767166
18.

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, Bando M, Ohno S, Ishikawa Y, Aburatani H, Niki T, Sohara Y, Sugiyama Y, Mano H.

Nature. 2007 Aug 2;448(7153):561-6. Epub 2007 Jul 11.

PMID:
17625570
19.

Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers.

Trusheim MR, Berndt ER, Douglas FL.

Nat Rev Drug Discov. 2007 Apr;6(4):287-93. Review.

PMID:
17380152
20.

Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients.

Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, Farrar K, Park BK, Breckenridge AM.

BMJ. 2004 Jul 3;329(7456):15-9.

Items per page

Supplemental Content

Write to the Help Desk